As the novel coronavirus (COVID-19) continues to spread across the world, our analysts are constantly tracking the impact of this rapidly evolving situation on the markets and the consumer purchase behaviours. Thus, our latest estimates and analysis about the current market trends and forecast will exhaustively reflect the effects of this emerging pandemic.

Global Doxorubicin Market: By Application: Ovarian Cancer, Multiple Myeloma, Kaposi Sarcoma, Leukaemia, Bone sarcoma, Breast cancer, Endometrial cancer, Gastric cancer, Liver cancer, Other Cancer; Regional Analysis; Historical Market and Forecast (2016-2026); Market Dynamics; Competitive Landscape; Industry Events and Developments

Global Doxorubicin Market Outlook

The global doxorubicin market attained a value of about USD 1,075.90 million in 2020. The market is further expected to grow in the forecast period of 2021-2026 at a CAGR of 6.4% to reach nearly USD 1,564.30 million by 2026.

 

Breast Cancer Segment to Hold a Significant Market Share of the Market Over the Forecast Period

Doxorubicin finds its largest regional market in North America. The region is expected to retain its dominance over the global market in the coming years owing to the increase in cancer incidence and associated mortality rate. The United States registered the highest cancer rate and considerable deaths in 2020. Meanwhile, the regional market in the Asia Pacific is estimated to grow with healthy CAGR over the period owing to the highest mortality rate in China.

 

Global Doxorubicin Market

Read more about this report - REQUEST FREE SAMPLE COPY IN PDF

 

In terms of application, the most prevalent cancers include breast cancer, prostate cancer, lung cancer, colon and rectum cancer, and skin melanoma. Hence, the segment of breast cancer is projected to account for the maximum use of the drug in the coming years. According to WHO, the number of breast cancer cases found in the year 2020 was around 2.26 million, which is about 11.7% of all the new cases registered that year.

 

Doxorubicin: Industry Definition and Segmentation

Doxorubicin (C27H29NO11) is a medication for chemotherapy used in the treatment of various cancer diseases, including breast cancer, bladder cancer, lymphoma, and others. It is administered as an intravenous drug along with other chemotherapy agents and is sold under different brand names including Adriamycin, and Caelyx, among others.

The applications for doxorubicin include:

  • Ovarian Cancer
  • Multiple Myeloma
  • Kaposi Sarcoma
  • Leukaemia
  • Bone Sarcoma
  • Breast Cancer
  • Endometrial Cancer
  • Gastric Cancer
  • Liver Cancer
  • Kidney Cancer
  • Other Cancer

The EMR report looks into the regional markets of doxorubicin like North America, Europe, the Asia Pacific, Latin America, and the Middle East and Africa.

 

Rising Cancer Cases and Related Deaths to Bolster the Demand for Doxorubicin

The primary driver for the market growth of doxorubicin is the rising incidences of cancer across the globe. This increase can be attributed to the presence of carcinogens in day-to-day use products in the current lifestyle of people. According to the latest statistics provided by the Union for International Cancer Control (UICC), the number of cancer cases has risen to 19.3 million and 10 million cancer related deaths in 2020. This rise is expected to continue in the forthcoming years, providing lucrative opportunities for demand growth of doxorubicin. Additionally, supportive actions from the government for technological progress in clinical diagnostics and therapeutics such as intravenous free therapy and digital microfluidics for biochemical analysis is expected to boost the market growth of the drug over the forecast period. However, it is noteworthy that certain side effects, such as hand-foot syndrome, typhlitis, heart failure, among others, can potentially impede the growing demand.

 

Key Industry Players in the Global Doxorubicin Market

The report presents a detailed analysis of the following key players in the global doxorubicin market, looking into their capacity, market shares, and latest developments like capacity expansions, plant turnarounds, and mergers and acquisitions:

  • Pfizer Inc.
  • Sun Pharmaceutical Industries Limited
  • Cipla, Inc.
  • Cadila Pharmaceuticals Ltd.
  • Others

The comprehensive report looks into the macro and micro aspects of the industry. The EMR report gives an in-depth insight into the market by providing a SWOT analysis as well as an analysis of Porter’s Five Forces model.

 

REPORT FEATURES DETAILS
Base Year 2020
Historical Period 2016-2020
Forecast Period 2021-2026
Scope of the Report Historical and Forecast Trends, Industry Drivers and Constraints, Historical and Forecast Market Analysis by Segment- Application, Region
Breakup by Application Ovarian Cancer, Multiple Myeloma, Kaposi Sarcoma, Leukaemia, Bone sarcoma, Breast cancer, Endometrial cancer, Gastric cancer, Liver cancer, Kidney cancer, Other Cancer
Breakup by Region North America, Europe, Asia Pacific, Latin America, Middle East and Africa
Market Dynamics SWOT, Porter's Five Forces, EMR’s Key Indicators for Price and Demand
Competitive Landscape Market Structure, Company Profiles- Company Overview, Product Portfolio, Demographic Reach and Achievements, Certifications
Companies Covered Pfizer Inc., Sun Pharmaceutical Industries Limited, Cipla, Inc., Cadila Pharmaceuticals Ltd., Others
Report Price and Purchase Option Explore our purchase options that are best suited to your resources and industry needs.
Delivery Format Delivered as an attached PDF and Excel through email, with an option of receiving an editable PPT, according to the purchase option.

 

*We at Expert Market Research always thrive to give you the latest information. The numbers in the article are only indicative and may be different from the actual report.

1    Preface
2    Report Coverage – Key Segmentation and Scope
3    Report Description

    3.1    Market Definition and Outlook
    3.2    Properties and Applications
    3.3    Market Analysis
    3.4    Key Players
4    Key Assumptions
5    Executive Summary

    5.1    Overview
    5.2    Key Drivers
    5.3    Key Developments
    5.4    Competitive Structure
    5.5    Key Industrial Trends
6    Snapshot
    6.1    Global
    6.2    Regional
7    Industry Opportunities and Challenges
8    Global Doxorubicin Market Analysis

    8.1    Key Industry Highlights
    8.2    Global Doxorubicin Historical Market (2016-2020) 
    8.3    Global Doxorubicin Market Forecast (2021-2026)
    8.4    Global Doxorubicin Market by Application
        8.4.1    Ovarian Cancer
            8.4.1.1    Market Share
            8.4.1.2    Historical Trend (2016-2020)
            8.4.1.3    Forecast Trend (2021-2026)
        8.4.2    Multiple Myeloma
            8.4.2.1    Market Share
            8.4.2.2    Historical Trend (2016-2020)
            8.4.2.3    Forecast Trend (2021-2026)
        8.4.3    Kaposi Sarcoma
            8.4.3.1    Market Share
            8.4.3.2    Historical Trend (2016-2020)
            8.4.3.3    Forecast Trend (2021-2026)
        8.4.4    Leukaemia
            8.4.4.1    Market Share
            8.4.4.2    Historical Trend (2016-2020)
            8.4.4.3    Forecast Trend (2021-2026)
        8.4.5    Bone sarcoma
            8.4.5.1    Market Share
            8.4.5.2    Historical Trend (2016-2020)
            8.4.5.3    Forecast Trend (2021-2026)
        8.4.6    Breast cancer
            8.4.6.1    Market Share
            8.4.6.2    Historical Trend (2016-2020)
            8.4.6.3    Forecast Trend (2021-2026)
        8.4.7    Endometrial cancer
            8.4.7.1    Market Share
            8.4.7.2    Historical Trend (2016-2020)
            8.4.7.3    Forecast Trend (2021-2026)
        8.4.8    Gastric cancer
            8.4.8.1    Market Share
            8.4.8.2    Historical Trend (2016-2020)
            8.4.8.3    Forecast Trend (2021-2026)
        8.4.9    Liver cancer
            8.4.9.1    Market Share
            8.4.9.2    Historical Trend (2016-2020)
            8.4.9.3    Forecast Trend (2021-2026)
        8.4.10    Kidney cancer
            8.4.10.1    Market Share
            8.4.10.2    Historical Trend (2016-2020)
            8.4.10.3    Forecast Trend (2021-2026)
        8.4.11    Other Cancer
    8.5    Global Doxorubicin Market by Region
        8.5.1    Market Share
            8.5.1.1    North America
            8.5.1.2    Europe
            8.5.1.3    Asia Pacific
            8.5.1.4    Latin America
            8.5.1.5    Middle East and Africa
9    Regional Analysis
    9.1    North America
        9.1.1    Historical Trend (2016-2020)
        9.1.2    Forecast Trend (2021-2026)
        9.1.3    Breakup by Country
            9.1.3.1    United States of America 
            9.1.3.2    Canada
    9.2    Europe
        9.2.1    Historical Trend (2016-2020)
        9.2.2    Forecast Trend (2021-2026)
        9.2.3    Breakup by Country 
            9.2.3.1    United Kingdom
            9.2.3.2    Germany
            9.2.3.3    France
            9.2.3.4    Italy
            9.2.3.5    Others
    9.3    Asia Pacific
        9.3.1    Historical Trend (2016-2020)
        9.3.2    Forecast Trend (2021-2026)
        9.3.3    Breakup by Country
            9.3.3.1    China
            9.3.3.2    Japan
            9.3.3.3    India
            9.3.3.4    ASEAN
            9.3.3.5    Australia
            9.3.3.6    Others
    9.4    Latin America
        9.4.1    Historical Trend (2016-2020)
        9.4.2    Forecast Trend (2021-2026)
        9.4.3    Breakup by Country
            9.4.3.1    Brazil
            9.4.3.2    Argentina
            9.4.3.3    Mexico
            9.4.3.4    Others
    9.5    Middle East and Africa
        9.5.1    Historical Trend (2016-2020)
        9.5.2    Forecast Trend (2021-2026)
        9.5.3    Breakup by Country
            9.5.3.1    Saudi Arabia
            9.5.3.2    United Arab Emirates
            9.5.3.3    Nigeria
            9.5.3.4    South Africa
            9.5.3.5    Others
10    Market Dynamics
    10.1    SWOT Analysis
        10.1.1    Strengths
        10.1.2    Weaknesses
        10.1.3    Opportunities
        10.1.4    Threats
    10.2    Porter’s Five Forces Analysis
        10.2.1    Supplier’s Power
        10.2.2    Buyer’s Power
        10.2.3    Threat of New Entrants
        10.2.4    Degree of Rivalry
        10.2.5    Threat of Substitutes
    10.3    EMR’s Key Indicators for Demand
    10.4    EMR’s Key Indicators for Price
11    Value Chain Analysis
12    Competitive Landscape

    12.1    Market Structure
    12.2    Company Profiles
        12.2.1    Pfizer Inc.
            12.2.1.1    Company Overview
            12.2.1.2    Product Portfolio
            12.2.1.3    Demographic Reach and Achievements
            12.2.1.4    Certifications
        12.2.2    Sun Pharmaceutical Industries Limited
            12.2.2.1    Company Overview
            12.2.2.2    Product Portfolio
            12.2.2.3    Demographic Reach and Achievements
            12.2.2.4    Certifications
        12.2.3    Cipla, Inc.
            12.2.3.1    Company Overview
            12.2.3.2    Product Portfolio
            12.2.3.3    Demographic Reach and Achievements
            12.2.3.4    Certifications
        12.2.4    Cadila Pharmaceuticals Ltd.
            12.2.4.1    Company Overview
            12.2.4.2    Product Portfolio
            12.2.4.3    Demographic Reach and Achievements
            12.2.4.4    Certifications
        12.2.5    Others
13    Industry Events and Developments

 

Additional Customisations Available

1    Manufacturing Process
    1.1    Overview
    1.2    Detailed Process Flow
    1.3    Operation Involved

 

List of Figures and Tables

1.    Global Doxorubicin Market: Key Industry Highlights, 2016 and 2026
2.    Global Doxorubicin Historical Market: Breakup by Application (USD Million), 2016-2020
3.    Global Doxorubicin Market Forecast: Breakup by Application (USD Million), 2021-2026
4.    Global Doxorubicin Historical Market: Breakup by Region (USD Million), 2016-2020
5.    Global Doxorubicin Market Forecast: Breakup by Region (USD Million), 2021-2026
6.    North America Doxorubicin Historical Market: Breakup by Country (USD Million), 2016-2020
7.    North America Doxorubicin Market Forecast: Breakup by Country (USD Million), 2021-2026
8.    Europe Doxorubicin Historical Market: Breakup by Country (USD Million), 2016-2020
9.    Europe Doxorubicin Market Forecast: Breakup by Country (USD Million), 2021-2026
10.    Asia Pacific Doxorubicin Historical Market: Breakup by Country (USD Million), 2016-2020
11.    Asia Pacific Doxorubicin Market Forecast: Breakup by Country (USD Million), 2021-2026
12.    Latin America Doxorubicin Historical Market: Breakup by Country (USD Million), 2016-2020
13.    Latin America Doxorubicin Market Forecast: Breakup by Country (USD Million), 2021-2026
14.    Middle East and Africa Doxorubicin Historical Market: Breakup by Country (USD Million), 2016-2020
15.    Middle East and Africa Doxorubicin Market Forecast: Breakup by Country (USD Million), 2021-2026
16.    Global Doxorubicin Market Structure

Key Questions Answered in the Report

The global doxorubicin market attained a value of nearly USD 1,075.90 million in 2020.

The market is projected to grow at a CAGR of 6.4% in the forecast period of 2021-2026.

The market is estimated to witness healthy growth in the forecast period of 2021-2026 to reach about USD 1,564.30 million by 2026.

The market is being driven by the rising cases of cancer and the associated mortality rates, along with an increase in the number of breast cancer patients worldwide.

The industry is primarily being driven the supportive actions from the government for technological progress in clinical diagnostics and therapeutics.

The major regional markets for doxorubicin are North America, Latin America, the Asia Pacific, Europe, and the Middle East and Africa.

Doxorubicin finds its applications in the treatment of ovarian cancer, multiple myeloma, kaposi sarcoma, leukaemia, bone sarcoma, breast cancer, endometrial cancer, gastric cancer, liver cancer, and kidney cancer, among other types of cancers.

The major players in the industry are Pfizer Inc., Sun Pharmaceutical Industries Limited, Cipla, Inc., and Cadila Pharmaceuticals Ltd., among others.

Analyst Review

The global doxorubicin market attained a value of about USD 1,075.90 million in 2020, driven by the rising cases of cancer worldwide. Aided by government investments in the pharmaceutical sector, the market is expected to grow at a CAGR of 6.4% in the forecast period of 2021-2026 to reach nearly USD 1,564.30 million by 2026.

EMR's meticulous research methodology delves deep into the market, covering the macro and micro aspects of the industry. Based on applications, the market can be classified into ovarian cancer, multiple myeloma, kaposi sarcoma, leukaemia, bone sarcoma, breast cancer, endometrial cancer, gastric cancer, liver cancer, and kidney cancer, among other types of cancers. The major regional markets for doxorubicin are North America, Latin America, the Asia Pacific, Europe, and the Middle East and Africa. The key players in the industry are Pfizer Inc., Sun Pharmaceutical Industries Limited, Cipla, Inc., and Cadila Pharmaceuticals Ltd., among others.

EMR's research methodology uses a combination of cutting-edge analytical tools and the expertise of their highly accomplished team, thus providing their customers with market insights that are accurate, actionable and help them remain ahead of their competition.

Purchase Full Report

Mini Report

$1499
  • Selected Sections, One User
  • Printing Not Allowed
  • Email Delivery in PDF
  • Free Limited Customisation
  • Post Sales Analyst Support
  • 50% Discount on Next Update

Single User License

$2699
  • All Sections, One User
  • One Print Allowed
  • Email Delivery in PDF
  • Free Limited Customisation
  • Post Sales Analyst Support
  • 50% Discount on Next Update

Five User License

$3699
  • All Sections, Five Users
  • Five Prints Allowed
  • Email Delivery in PDF
  • Free Limited Customisation
  • Post Sales Analyst Support
  • 50% Discount on Next Update

Corporate License

$4699
  • All Sections, Unlimited Users
  • Unlimited Prints Allowed
  • Email Delivery in PDF + Excel
  • Free Limited Customisation
  • Post Sales Analyst Support
  • 50% Discount on Next Update

Any Question? Speak With An Analyst

Contact Analyst

View A Sample

Request Sample

Did You Miss Anything, Ask Now

Request Customisation
Why Expert Market Research?

RIGHT PEOPLE

We are technically excellent, strategic, practical, experienced and efficient; our analysts are hand-picked based on having the right attributes to work successfully and execute projects based on your expectations.

RIGHT METHODOLOGY

We leverage our cutting-edge technology, our access to trusted databases, and our knowledge of the current models used in the market to deliver you research solutions that are tailored to your needs and put you ahead of the curve.

RIGHT PRICE

We deliver in-depth and superior quality research in prices that are reasonable, unmatchable, and shows our understanding of your resource structure. We, additionally, offer attractive discounts on our upcoming reports.

RIGHT SUPPORT

Our team of expert analysts are at your beck and call to deliver you optimum results that are customised to meet your precise needs within the specified timeframe and help you form a better understanding of the industry.

Similar Reports





NEWSLETTER